Revvity reported adjusted earnings of $1.70 per share for Q4 2025, representing a 19.7% increase from $1.42 per share in the year-ago period and surpassing the consensus estimate of $1.55. Revenue rose to $772.06 million, up 6% year-over-year (4% on an organic basis), outperforming the Street forecast of $761.29 million. The life sciences and diagnostics division led growth with a mid-single-digit organic sales gain, driven by strong demand for diagnostic reagents and laboratory automation solutions.

For fiscal 2026, Revvity issued guidance of $5.35 to $5.45 in adjusted earnings per share, above the consensus of $5.32, and projected revenue between $2.96 and $2.99 billion, exceeding the Street view of $2.93 billion. This outlook implies overall growth of 4%–5% and organic expansion of 2%–3%, underpinned by the company’s portfolio transformation efforts and anticipated improvement in academic and biopharma research funding trends.

Following the stronger-than-expected quarter, several brokerages raised their 2026 EPS forecasts for Revvity by an average of $0.05 and lifted revenue estimates by roughly $50 million. Price targets were revised upward by a median of 8%, reflecting confidence in sustained margin expansion and the resilience of the diagnostics business. Analysts highlighted the potential for further upside from recent product launches in next-generation sequencing and mass spectrometry platforms.